相关实验视频
Updated: Jul 4, 2025

11:58
Primary Culture of Mouse Dopaminergic Neurons
Published on: September 8, 2014
38.0K
多巴胺修饰甘油酶会损害甘油分解:对帕金森病的可能影响
Bing Chen1,2, Qian Zhang1,3,4, Xiaoru Zhong1
1Shenzhen Clinical Research Center for Geriatrics and Shenzhen Institute of Respiratory Disease, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, China.
Cell communication and signaling : CCS
|January 30, 2024
概括
多巴胺修改了关键的甘油酶,损害了帕金森病 (PD) 中的ATP生产和线粒体功能. 保护葡萄糖分解免受多巴胺损伤可能为PD提供新的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 分子生物学分子生物学
背景情况:
- 帕金森病 (PD) 涉及多巴胺能神经元的损失.
- 多巴胺 (DA) 和其代谢物可以修改蛋白质,从而导致PD的发病.
- 在PD中多巴胺修饰的特定蛋白质点在很大程度上仍然未知.
研究的目的:
- 通过基于活动的蛋白质分析 (ABPP) 来识别多巴胺修饰的蛋白质标.
- 研究多巴胺与已识别的蛋白标结合的功能后果.
- 探索潜在的治疗策略,针对PD中的糖解.
主要方法:
- 为ABPP设计和合成了一种多巴胺探针 (DA-P).
- 使用液体染色学-双重质谱法 (LC-MS/MS) 来识别目标.
- 使用现场拉下测试,CETSA和免疫光检测证实了DA修改.
- 评估了酶活性,糖解压力,线粒体呼吸和代谢概况.
主要成果:
- 确定了阿尔多酶A,α-酶和酸盐激酶M2 (PKM2) 作为多巴胺结合蛋白.
- 多巴胺结合抑制了α-enolase和PKM2.2的酶活性.
- 失效的糖解导致ATP合成减少和线粒体功能障碍.
结论:
- 糖解路易受多巴胺诱导的PD中断的影响.
- 多巴胺抑制关键的糖解酶会损害细胞能量生产.
- 保护葡萄糖溶解免受多巴胺损伤,为帕金森病提供了潜在的治疗途径.
相关概念视频
Parkinson's Disease: Overview
547
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
547
Parkinson's Disease: Treatment
268
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
268
Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
Neural Regulation
39.4K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.4K
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
323
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
323

